High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa.
COVID-19
Cross-reactivity
HCoV-229E
HCoV-NL63
Human coronavirus
SARS-CoV-2
Serology
Sub-Saharan Africa
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
01
10
2020
revised:
27
10
2020
accepted:
31
10
2020
pubmed:
12
11
2020
medline:
20
1
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Significant morbidity and mortality have occurred in the USA, Europe, and Asia due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), whereas the numbers of infections and deaths in sub-Saharan Africa (SSA) have remained comparatively low. It has been hypothesized that exposure of the population in SSA to other coronaviruses prior to the COVID-19 pandemic resulted in some degree of cross-protection against SARS-CoV-2 infection and pathogenesis. We evaluated this hypothesis by comparing SARS-CoV-2 cross-reactive antibodies in pre-pandemic plasma samples collected from SSA and the USA. Pre-COVID-19 pandemic plasma samples from SSA and the USA were collected and tested by immunofluorescence assay against the spike and nucleocapsid proteins of all known human coronaviruses (HCoVs). The prevalence of SARS-CoV-2 serological cross-reactivity was significantly higher in samples from SSA compared with the USA. Most of these cross-reactive samples cross-recognized the SARS-CoV-2 nucleocapsid protein and the spike proteins of other HCoVs. Nucleocapsid proteins from HCoV-NL63 and HCoV-229E were detected in most samples, thereby implicating prior exposure to these two HCoVs as the likely source of cross-reactive antibodies against SARS-CoV-2. The low incidences of SARS-CoV-2 infection and disease in SSA appear to be correlated with the pre-pandemic serological cross-recognition of HCoVs, which are substantially more prevalent in SSA than the USA.
Identifiants
pubmed: 33176202
pii: S1201-9712(20)32310-9
doi: 10.1016/j.ijid.2020.10.104
pmc: PMC7648883
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Nucleocapsid Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
577-583Subventions
Organisme : NCI NIH HHS
ID : R25 CA112383
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW001429
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103427
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW011095
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190155
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW011418
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA221204
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010354
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6
pubmed: 18382647
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
J Clin Microbiol. 2010 Aug;48(8):2940-7
pubmed: 20554810
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15193-15199
pubmed: 32522874
Nat Med. 2020 Jul;26(7):996-999
pubmed: 32528153
Clin Med (Lond). 2015 Feb;15(1):54-7
pubmed: 25650199
Nat Microbiol. 2020 Nov;5(11):1408-1417
pubmed: 32724171
J Infect Dis. 2005 Feb 15;191(4):492-8
pubmed: 15655770
Open Virol J. 2010 May 25;4:76-84
pubmed: 20700397
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93
pubmed: 15897467
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Cancer Med. 2016 May;5(5):914-28
pubmed: 26823008
Signal Transduct Target Ther. 2020 Jun 10;5(1):89
pubmed: 32533062